A September 2026 company announcement states that an unnamed MSD candidate using its oral technology entered Phase 1. The candidate structure is not disclosed, so it cannot be classified as a cyclic peptide.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A September 2026 company announcement states that an unnamed MSD candidate using its oral technology entered Phase 1. The candidate structure is not disclosed, so it cannot be classified as a cyclic peptide.
2026-09-29: Delivery-platform reference: Cyprumed technology enters its first human trial with MSD
Program / service
Target / indication
Representative stage
Evidence & scope
Unnamed MSD oral candidate
Not disclosed · Not disclosed
Phase 1
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Cyprumed announced that MSD initiated a Phase 1 trial using its licensed oral tablet technology, triggering a milestone payment. The candidate and its structural class were undisclosed, so the program cannot be identified as a cyclic peptide. The earlier agreement’s potential $493 million comprises upfront and milestone payments, rather than cash already received. This is included as a delivery-platform reference.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
